Amgen Inc. SEC filings document the regulatory record for a Nasdaq-listed biotechnology company with common stock and registered debt securities. Its 8-K reports cover quarterly and annual earnings releases, Regulation G reconciliations for non-GAAP measures, free cash flow disclosures, material definitive agreements, executive leadership changes and capital markets transactions.
The company's proxy materials describe annual meeting matters, board governance, executive compensation and stockholder voting procedures. Other filings address senior note offerings under registration statements and indentures, Nasdaq listing and registration matters for debt securities, and formal exhibits that define the terms of financing, governance and corporate disclosure events.
Amgen Inc. EVP of Research and Development James E. Bradner reported a small tax-related share disposition. On the reported date, 446 shares of common stock were withheld at $331.11 per share to satisfy tax obligations, a non-market transaction classified as a tax-withholding disposition.
After this event, Bradner directly held 30,016 Amgen shares. The reported holdings include 1,273 dividend equivalents tied to unvested restricted stock units that will pay out in Amgen common stock as they vest, along with cash for any fractional share amounts.
Amgen Inc. executive James E. Bradner reported routine equity compensation activity. On May 5, 2026, he acquired 3,337 Restricted Stock Units (RSUs) at $0.00 per share, which vest in four equal annual installments of 25% each starting on May 5, 2027. These shares include 1,332 Dividend Equivalents (DEs) that will be paid in common stock following the same vesting schedule. He was also granted 21,773 non-qualified stock options with a $329.59 exercise price, vesting 25% annually from May 5, 2027 and expiring on May 5, 2036. On May 6, 2026, 407 shares of common stock were disposed of at $329.59 per share to cover tax obligations, a non-market tax-withholding disposition. After these transactions, Bradner directly holds 30,462 shares of Amgen common stock.
Amgen Inc. Chairman, CEO and President Robert A. Bradway reported routine equity compensation and related tax withholding. On May 5, 2026, he received 12,136 Restricted Stock Units (RSUs) at $0.00 per share and 79,176 non-qualified stock options with a $329.59 exercise price, all granted under Amgen’s Equity Incentive Plan.
The RSUs and options each vest in four equal annual installments of 25% starting on May 5, 2027, with vested RSUs settled in common shares and the options exercisable through May 5, 2036. A separate F-code transaction on May 6, 2026 reflects 1,702 shares used to satisfy tax obligations at $329.59 per share, not an open-market sale. After these transactions, Bradway directly holds 507,239 common shares, in addition to indirect holdings by his spouse and related GRATs.
Amgen executive Matthew C. Busch, VP Finance & CAO, reported routine equity compensation grants and related tax withholding. He received 455 shares of common stock as Restricted Stock Units, including 45 Dividend Equivalents, under Amgen’s Equity Incentive Plan. These RSUs vest in four equal 25% installments starting on 5/5/2027 and are settled in common shares.
Busch also received 2,969 non-qualified stock options with a $329.59 exercise price, vesting 25% annually from 5/5/2027 until expiration on 5/5/2036. To cover tax obligations, 50 shares of common stock were disposed of at $329.59 per share as a tax-withholding transaction, not an open-market sale. After these transactions, he directly holds 4,385 common shares.
Amgen EVP Murdo Gordon reported new equity awards and a small tax-related share withholding. On May 5, 2026, he received 3,640 Restricted Stock Units (RSUs) that vest in four equal annual installments of 25% starting on May 5, 2027, and will be settled in common shares. These RSUs include 458 Dividend Equivalents credited under Amgen’s Equity Incentive Plan. He was also granted 23,752 non-qualified stock options with a $329.59 exercise price, vesting 25% annually from May 5, 2027, and expiring on May 5, 2036. On May 6, 2026, 502 shares of common stock were disposed of at $329.59 per share to satisfy tax obligations, a non-market "F" code withholding. After these transactions, Gordon directly holds 51,837 Amgen common shares.
Amgen Inc. executive vice president and general counsel Jonathan P. Graham reported routine equity compensation changes. On May 5, 2026, he received 2,609 shares of common stock at no cost as a grant, increasing his direct holdings to 40,619 shares. The same day, he was granted 17,022 non-qualified stock options with an exercise price of $329.59 per share, exercisable in four equal annual installments starting May 5, 2027 and expiring in 2036. These options relate to an equal number of underlying common shares. On May 6, 2026, 408 shares were disposed of at $329.59 per share to satisfy tax obligations, leaving him with 40,211 shares held directly. The restricted stock units and options vest in four annual installments of 25% each beginning in 2027, and vested RSUs and related dividend equivalents will be settled in common shares on a one-to-one basis.
Amgen EVP & CFO Peter H. Griffith reported routine equity compensation and related tax withholding. On May 5, 2026, he received 3,640 shares of Common Stock as a grant valued at $0.0000 per share, tied to Restricted Stock Units under Amgen’s Equity Incentive Plan. These RSUs, including 424 Dividend Equivalents, vest in four equal 25% installments starting on May 5, 2027 and will be settled in common shares.
He was also granted 23,752 non-qualified stock options with a $329.59 exercise price, vesting 25% annually from May 5, 2027 and expiring on May 5, 2036. On May 6, 2026, 502 shares of Common Stock were disposed of at $329.59 per share to cover tax obligations. After these transactions, he directly holds 50,706 shares of Amgen common stock.
Amgen SVP & CCO Nancy A. Grygiel reported routine equity compensation activity. She received 485 shares of common stock as a grant, increasing her direct holdings to 7,494 shares, and was granted 3,167 non-qualified stock options at $329.59 per share, vesting in four annual installments starting on May 5, 2027.
The filing also shows 76 shares were withheld at $329.59 per share to cover tax obligations, leaving 7,418 directly held shares afterward. The stock grant consists of Restricted Stock Units that convert one-for-one into common shares as they vest, and the options are exercisable in equal parts through May 5, 2030 with an expiration on May 5, 2036. An indirect 401(k) holding of 106.1864 shares is also reported.
Amgen Inc. senior vice president Rachna Khosla reported routine equity compensation changes. On May 5, 2026, she received an award of 500 shares of common stock at $0.00 per share and a grant of 3,266 non-qualified stock options with a $329.59 exercise price, all under Amgen’s Equity Incentive Plan. The options and related Restricted Stock Units vest in four equal annual installments of 25% each, beginning on May 5, 2027. On May 6, 2026, 79 shares of common stock at $329.59 were withheld to cover tax obligations. After these transactions, she directly holds 8,487 shares of Amgen common stock.
Amgen Inc. senior vice president of human resources Derek Miller reported routine equity compensation activity. He received 910 shares of common stock as a grant, which the footnotes describe as Restricted Stock Units that vest in four equal annual installments of 25% starting on May 5, 2027, and include 116 Dividend Equivalents credited under Amgen’s equity incentive plan.
He was also granted 5,938 non-qualified stock options with an exercise price of $329.59 per share, vesting 25% per year from May 5, 2027 until expiration on May 5, 2036. Separately, 123 shares of common stock were disposed of at $329.59 per share to cover tax obligations, a non-market tax-withholding transaction. After these transactions, Miller directly holds 12,595 Amgen shares.